The epidemiology of glucocorticoid-associated adverse events

Current Opinion in Rheumatology

Volumn 20, Issue 2, 2008, Pages 131-137

  McDonough, Allyson K ^a   Curtis, Jeffrey R ^a   Saag, Kenneth G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Adverse events; Epidemiology; Glucocorticoid

Indexed keywords

GLUCOCORTICOID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ACNE VULGARIS; ANXIETY; APPETITE; ATHEROSCLEROSIS; BACTERIAL INFECTION; BONE NECROSIS; BRAIN PSEUDOTUMOR; CARDIOVASCULAR DISEASE; CATARACT; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DEPRESSION; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG USE; EUPHORIA; FATTY LIVER; FRACTURE; FRAGILITY FRACTURE; GLAUCOMA; GLUCOSE BLOOD LEVEL; GROWTH RETARDATION; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; INFECTION RISK; INFLAMMATION; INSOMNIA; IRRITABILITY; LONG TERM CARE; LOW DRUG DOSE; MANIA; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; MUSCLE CRAMP; MUSCLE WEAKNESS; MYOPATHY; NEUROLOGIC DISEASE; OSTEOPOROSIS; PANCREATITIS; PEDIATRICS; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; SKIN ATROPHY; SKIN BRUISING; SLEEP DISORDER; TREATMENT DURATION; WEIGHT GAIN; WOUND HEALING;

ADULT; CHILD; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; LONGITUDINAL STUDIES; MIDDLE AGED; OSTEOPOROSIS; RHEUMATIC DISEASES;

EID: 40349092811     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f51031     Document Type: Review

References (46)

1. Pisu M, James N, Sampsel S, Saag KG, et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:781-788.
2. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM 2000; 93:105-111.
3. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65:285-293.
4. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004; 15:323-328.
5. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 2006; 54:628-634. This large observational study of patients with RA in the National Databank for Rheumatic Disease cohort. Glucocorticoid use (mean dose 5 mg/kg) was associated with an increased risk of hospitalization for pneumonia and this association showed a dose-related increase in risk. Interestingly the risk associated with antitumor necrosis factor therapies was much less than glucocorticoids despite theoretical concerns about increased risk of infection.
6. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46:2294-2300.
7. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006; 63:2451-2465.
8. Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000.
9. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39:253-259. This cross-sectional Italian study found increased incidence of asymptomatic vertebral fracture in patients with a variety of underlying diseases requiring chronic glucocorticoid use (>1350 mg cumulative dose equivalent). This study cannot separate disease-specific outcomes from glucocorticoid-associated ones. As seen in other studies low BMD did not correlate with fracture occurrence.
10. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55:420-426. This large population study linked administrative and pharmacy data determined glucocorticoid use patterns, fractures, and self-reported adverse events. A strong dose-response relationship between glucocorticoids and a wide variety of adverse events was noted.
11. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157:142-148.
12. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777-787.
13. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002; 61:32-36.
14. Kanis JA, Stevenson M, McCloskey EV, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893-899.
15. Natsui K, Tanaka K, Suda M, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int 2006; 17:105-108. Therapy with high-dose glucocorticoids caused significant decline in BMD even in the first 2 months of therapy. Muscle mass also declined significantly.
16. Summey BT, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol 2006; 142:82-90.
17. Shah SK, Gecys GT. Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect. J Am Osteopath Assoc 2006; 106:653-657.
18. Saag KG, Gehlbach SH, Curtis JR, et al. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 2006; 33:1651-1657.
19. Saag KG, Gehlbach SH, Curtis JR, et al. Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 2006; 33:1651-1657. This study looks at screening and treatment rates for glucocorticoid induced osteoporosis.
20. Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid- induced osteoporosis: an update. Trends Endocrinol Metab 2006; 17:144-149.
21. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48:3224-3229.
22. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79:129-137.
23. De Vries F, Bracke M, Leufkens HG, et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007; 56:208-214. This study using the UK General Practice Research Database found that low daily dose prednisone with high cumulative doses increases the risk for osteoporotic fracture. Intermittent high-dose regimens with cumulative doses less than 1 g did not show increased risk. Risk declines rapidly after discontinuation of the glucocorticoids.
24. Lee C, Almagor O, Dunlop DD, et al. Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 2006; 45:53-60. This cross-sectional study found that systemic lupus erythematosus disease activity was a better predictor of low BMD than glucocorticoid use.
25. Popp AW, Isenegger J, Buerqi AW, et al. Glucocorticosteroid- induced spinal osteoporosis: scientific update on pathophysiology and treatment. Eur Spine J 2006; 15:1035-1049.
26. Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66:308-312. This prospective cohort study of patients with inflammatory polyarthritis determined that use of glucocorticoids was identified as an independent risk factor for hospitalization for infection.
27. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:1754-1764. This cohort study of patients with RA found that glucocorticoid use doubled the rate of serious bacterial infections compared with methotrexate use.
28. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4:621-630. Prospective clinical trial looking at safety outcomes in patients with Crohn's on a variety of therapies. After multivariate logistic regression analysis prednisone use was found to be an independent risk factor for infection.
29. Jick SS, Lieberman ES, Rahman MU, Choi HK, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55:19-26. A large, case-controlled epidemiological study of all cases of tuberculosis in the UK during 1990-2000 found patients with tuberculosis were nearly five times more likely to have been using glucocorticoids at the time of their diagnosis.
30. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764-770.
31. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90:859-865.
32. Maradit Kremers H, Reinalda MS, Crowson CS, et al. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007; 57:279-286. In a cohort of polymyalgia rheumatica patients looking at glucocorticoid use and cardiovascular outcomes, patients who received glucocorticoids did not have a significantly higher risk for myocardial infarction, heart failure, peripheral vascular disease, or cerebrovascular disease compared with those who did not receive glucocorticoids.
33. Chrousos GP, Kino T. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 2007; 10:213-219.
34. Hibberd C, Yau JL, Seckl JR. Glucocorticoids and the ageing hippocampus. J Anat 2000; 197:553-562.
35. Fusar-Poli P, Lazzaretti M, Ceruti M, et al. Depression after lung transplantation: causes and treatment. Lung 2007; 185:55-65.
36. Brown ES, Beard L, Frol AB, Rush AJ, et al. Effect of two prednisone exposures on mood and declarative memory. Neurobiol Learn Mem 2006; 86:28-34. Thirty human volunteers, with no history of systemic prescription corticosteroid therapy, were given two 3-day exposures of prednisone (60 mg/day) and one of identical placebo, with 11-day washouts between each medication exposure. Before and after each 3-day prednisone/placebo exposure, declarative memory was assessed using several validated tests, while mood was assessed with a variety of validated scales. No significant mood changes were found, although a significant decrease in aspects of memory performance was observed after the first prednisone exposure.
37. Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684. This was a double-blind randomized placebo-controlled trial of patients with acute respiratory distress syndrome who received methylprednisilone or placebo. Methylprednisilone was associated with higher rates of mortality. Compared with placebo, methylprednisolone did not increase the rate of infectious complications but was associated with a higher rate of neuromuscular weakness. The increased rate of neuromyopathy was not seen on further retrospective chart review.
38. Lee HJ, Oran B, Saliba RM, et al. Steroid myopathy in patients with acute graftversus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 2006; 38:299-303. This is a retrospective analysis of patients on high-dose glucocorticoids for treatment of acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Steroid myopathy was identified in 41% of patients and was generally of moderate severity.
39. Uchida K, Araki T, Toiyama Y, et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis Colon Rectum 2006; 49:74-79. This retrospective chart review of pediatric and adult patients with ulcerative colitis who underwent total proctocolectomy and ileal J-pouch-anal anastomosis looked at the relationship between the preoperative dose of glucocorticoids and major steroid-related complications. Significantly higher incidences of growth retardation, osteoporosis, glaucoma, and cataracts were noted in pediatric patients than in adult patients. In pediatric patients, major steroid-related complications occurred at a significantly lower preoperative total dosage of glucocorticoids/body weight or preoperative total dosage of glucocorticoids/body surface area.
40. van Staa TP, Cooper C, Leufkens HG, Bishop N, et al. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18:913-918.
41. King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 2007; 68:1607-1613. This is a retrospective chart review of boys with dystrophinopathies treated with steroids for at least 1 year compared with boys who had never been treated with steroids. Vertebral compression fractures occurred in 32% of the treated group, whereas no vertebral fractures were discovered in the steroid-naive group. Long bone fractures were 2.6 times greater in steroid-treated patients.
42. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007; 119 (Suppl 2):S166-S174.
43. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006; 43:42-51. This cross-sectional study looked at a cohort of pediatric patients with inflammatory bowel disease and 52 healthy controls to determine BMD reference values.
44. Seckl JR, Holmes MC. Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology. Nat Clin Pract Endocrinol Metab 2007; 3:479-488.
45. Crowther CA, Haslam RR, Hiller JE CA, et al. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006; 367:1913-1919.
46. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560-1567. Ten recommendations based on systematically retrieved research evidence and expert consensus through the Delphi process.